New drug combo shows promise for Tough-to-Treat prostate cancer
NCT ID NCT06909825
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 3 times
Summary
This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at least one prior anti-androgen therapy and be in relatively good health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, 5037, Australia
-
Macquarie University Hospital
Macquarie Park, New South Wales, 2113, Australia
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out